Table 1.
Patient-specific Characteristics of the Other Group, all MCL2-treated, Trial-eligible (Stage II–IV, Age <66 Years, ECOG 0–2), and Trial-ineligible Patients
| Other | MCL2 | Trial Eligible | Trial Ineligible | Clinical MCL2 Trial |
|
|---|---|---|---|---|---|
| Patient number | 322 | 198 | 129 | 69 | 160 |
| Male | 229 (69.0%) | 153 (77.3%) | 104 (80.6%) | 49 (71.0%) | 113 (70.6%) |
| Median age, y | 75 (43–91) | 62 (27–79) | 59 (32–65) | 67 (27–79) | 56 (32–65) |
| <66 years | 39 (12.1%) | 145 (73.2%) | 129 (100%) | 16 (23.2%) | 160 (100%) |
| Stage | |||||
| I | 27 (8.4%) | <5 (2.5%) | 0 | <5 (7.1%) | 0 |
| II | 26 (8.1%) | 17 (8.5%) | 9 (7.0%) | 8 (11.4%) | 24 (15%) |
| III | 63 (19.6%) | 23 (11.6%) | 15 (11.6%) | 8 (11.4%) | |
| IV | 206 (63.9%) | 154 (77.4%) | 105 (81.4%) | 49 (68.1%) | 136 (85%) |
| ECOGa | |||||
| 0 | 80 (26.5%) | 92 (47.4%) | 65 (50.4%) | 27 (41.5%) | 148 (93%) |
| 1 | 137 (45.4%) | 77 (39.7%) | 54 (41.8%) | 23 (35.4%) | |
| 2 | 50 (16.6%) | 15a (7.7%) | 10 (7.8%) | <5 (7.7%) | 12 (7%) |
| 3 | 33 (10.9%) | 5 (2.6%) | 0 | 5 (7.7%) | 0 |
| 4 | <5 (1.6%) | <5 (2.6%) | 0 | <5 (7.7%) | 0 |
| MIPI risk groups | (15.9% missing) | (14.6% missing) | (17.0% missing) | (10.1% missing) | (1.9% missing) |
| Low | 12 (3.7%) | 45 (22.7%) | 38 (29.5%) | 7 (10.1%) | 79 (50%) |
| Intermediate | 78 (24.2%) | 71 (35.9%) | 42 (32.6%) | 29 (42.1%) | 41 (26%) |
| High | 181 (56.2%) | 53 (26.8%) | 27 (20.9%) | 26 (37.7%) | 37 (24%) |
aIn one of the centers, ECOG 0–2 patients were assigned to the same group (performance status at least ECOG 2).
ECOG = Eastern Cooperative Oncology Group; MCL = mantle cell lymphoma; MIPI = Mantle Cell Lymphoma International Prognostic Index.
The MCL2 trial patient characteristics, as referenced in the last column, have been adapted from Geisler et al.3